Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
Ampersand Biomedicines has raised $65.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Ampersand Biomedicines's investors include Eli Lilly, Flagship Pioneering.
Ampersand Biomedicines is headquartered in Boston, United States.
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
Ampersand Biomedicines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ampersand Biomedicines — Funding & Investors." VCBacked, March 19, 2025, https://www.vcbacked.co/company/ampersand-biomedicines. Accessed July 29, 2026.
VCBacked. (2025). Ampersand Biomedicines — Funding & Investors. Retrieved July 29, 2026, from https://www.vcbacked.co/company/ampersand-biomedicines
{{cite web |title=Ampersand Biomedicines — Funding & Investors |url=https://www.vcbacked.co/company/ampersand-biomedicines |website=VCBacked |access-date=July 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated